Chao Du1,2, Lijun Peng1, Guanjun Kou3,2, Peng Wang3,2, Lin Lu4, Yanqing Li5,6. 1. Department of Gastroenterology, Linyi People's Hospital, Shandong University, Linyi, 276000, Shandong, People's Republic of China. 2. Laboratory of Translational Gastroenterology, Qilu Hospital, Shandong University, Jinan, 250012, Shandong, People's Republic of China. 3. Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, 250012, Shandong, People's Republic of China. 4. Department of Gastroenterology, Linyi People's Hospital, Shandong University, Linyi, 276000, Shandong, People's Republic of China. lulingastro@126.com. 5. Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, 250012, Shandong, People's Republic of China. mx8902@163.com. 6. Laboratory of Translational Gastroenterology, Qilu Hospital, Shandong University, Jinan, 250012, Shandong, People's Republic of China. mx8902@163.com.
Abstract
BACKGROUND: Irritable bowel disease (IBS) is viewed upon as a functional disorder of subclinical inflammatory changes in recent years, and there is no reliable biomarker. Triggering receptor expressed on myeloid cells 1 (TREM-1), also produced in a soluble form (sTREM-1), is involved in the activation of inflammatory cascades of intracellular events and may play a role in pathogenesis of IBS. AIM: To investigate whether serum sTREM-1 level can be used as a marker of subclinical inflammation in D-IBS. METHODS: Abdominal pain was quantified by a validated questionnaire. Expression level of TREM-1 in colonic mucosa as well as sTREM-1 level in serum was also detected. Furthermore, we investigated the involvement of TREM-1-associated macrophage activation in IBS-like visceral hypersensitivity. RESULTS: No evidence for obvious inflammation was found in D-IBS patients. Serum sTREM-1 level in D-IBS patients was significantly higher than that in HCs, which was also significantly correlated with abdominal pain scores. We showed a marked increase in the proportion of TREM-1-expressing macrophages in D-IBS, which was significantly correlated with abdominal pain scores. Functionally, gadolinium chloride (GdCl3), a macrophage selective inhibitor, or LP17, the TREM-1-specific peptide, significantly suppressed the visceral hypersensitivity in trinitrobenzene sulfonic acid (TNBS)-treated mice with IBS-like visceral hypersensitivity. CONCLUSIONS: Serum sTREM-1 level is significantly higher in D-IBS patients and positively correlates with abdominal pain, which may be initiated by TREM-1-associated macrophage activation, indicating the existence of subclinical inflammation in D-IBS. Therefore, serum sTREM-1 is a potential marker of subclinical inflammation in D-IBS.
BACKGROUND:Irritable bowel disease (IBS) is viewed upon as a functional disorder of subclinical inflammatory changes in recent years, and there is no reliable biomarker. Triggering receptor expressed on myeloid cells 1 (TREM-1), also produced in a soluble form (sTREM-1), is involved in the activation of inflammatory cascades of intracellular events and may play a role in pathogenesis of IBS. AIM: To investigate whether serum sTREM-1 level can be used as a marker of subclinical inflammation in D-IBS. METHODS:Abdominal pain was quantified by a validated questionnaire. Expression level of TREM-1 in colonic mucosa as well as sTREM-1 level in serum was also detected. Furthermore, we investigated the involvement of TREM-1-associated macrophage activation in IBS-like visceral hypersensitivity. RESULTS: No evidence for obvious inflammation was found in D-IBSpatients. Serum sTREM-1 level in D-IBSpatients was significantly higher than that in HCs, which was also significantly correlated with abdominal pain scores. We showed a marked increase in the proportion of TREM-1-expressing macrophages in D-IBS, which was significantly correlated with abdominal pain scores. Functionally, gadolinium chloride (GdCl3), a macrophage selective inhibitor, or LP17, the TREM-1-specific peptide, significantly suppressed the visceral hypersensitivity intrinitrobenzene sulfonic acid (TNBS)-treated mice with IBS-like visceral hypersensitivity. CONCLUSIONS: Serum sTREM-1 level is significantly higher in D-IBSpatients and positively correlates with abdominal pain, which may be initiated by TREM-1-associated macrophage activation, indicating the existence of subclinical inflammation in D-IBS. Therefore, serum sTREM-1 is a potential marker of subclinical inflammation in D-IBS.
Authors: C C Bain; C L Scott; H Uronen-Hansson; S Gudjonsson; O Jansson; O Grip; M Guilliams; B Malissen; W W Agace; A McI Mowat Journal: Mucosal Immunol Date: 2012-09-19 Impact factor: 7.313